<DOC>
	<DOCNO>NCT02873767</DOCNO>
	<brief_summary>This study design evaluate safety tolerability single ascending dos UCB4019 administer subcutaneous injection healthy subject .</brief_summary>
	<brief_title>A First-In-Human Study With Single Dose UCB4019 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Good physical mental health At least 18 less 65 year age Female subject childbearing potential must agree use highly effective method birth control , study period 3 month last dose study drug Total Immunoglobulin G &lt; 7 g/L &gt; 16 g/L Screening Visit Absolute neutrophil count &lt; 1.5x10^9/L and/or lymphocyte count &lt; 1.0x10^9/L Known viral hepatitis , positive test Hepatitis B surface antigen Hepatitis C virus antibody positive Positive test Human Immunodeficiency Virus ( HIV ) 1/2 antibody Past medical history family history primary immunodeficiency Evidence latent/active Tuberculosis ( TB ) Active infection serious infection within 6 week first dose IMP Renal impairment Hepatic impairment Vaccination within 6 week Screening Visit intent vaccination Day 43 Safety Followup Period Subject splenectomized receive IMP experimental procedure within 90 day first dose IMP receive UCB7665 clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>First human</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>